Bristol Myers Squibb (BMY), a large U.S. drug firm focused on cancer, blood, and immune disease drugs, is teaming up with Anthropic to bring its Claude AI model to more than 30,000 staff members.
Claim 55% Off TipRanks
Explore NVDS for 2X short leverage on NVDAThe goal is clear: Bristol Myers wants to use AI to help speed up how it finds, tests, makes, and sells new drugs. The company also said it will use Claude Code, Anthropic’s coding tool, and test it across research, drug development, manufacturing, medical affairs, and sales work.
In short, this is not just about giving staff a chatbot. Bristol Myers wants Claude to help teams work with large pools of data that have long been hard to use. Greg Meyers, the company’s chief digital and technology officer, said, “Most enterprise AI stops at the chatbot. The real prize is the untapped value still trapped behind decades of data silos.”
Meanwhile, BMY shares rose 1.74% on Tuesday, closing at $58.31.
Pharma Keeps Betting on AI
Meanwhile, Bristol Myers is not alone. Drug firms are racing to see how AI can cut time, lower costs, and raise the odds that new drugs make it through trials. Eli Lilly (LLY), for example, has worked with Nvidia (NVDA) as part of its own AI push.
For investors, the key point is that this deal is a long-term play. It may not change Bristol Myers’ sales right away. However, if AI helps the company move faster in drug research and clinical work, it could support margins and growth over time.
That said, AI is still a tool, not a cure-all. Bristol Myers will need to show that Claude can do more than boost office speed. The real test will be whether it helps the company bring better drugs to market with less waste and more focus.
Is BMY a Good Stock to Buy Now?
Turning to the Street, Bristol Myers has a Moderate Buy consensus, based on 14 analysts’ ratings. The average MBY stock price target is $63.18, implying an 8.36% upside from the current price.
